All Updates

All Updates

icon
Filter
Partnerships
Seed Therapeutics partners with Eisai for molecular glue degraders development
Precision Medicine
Aug 7, 2024
This week:
Partnerships
T-Mobile partners with OpenAI to develop AI-powered customer service platform
Generative AI Applications
Yesterday
Partnerships
Runway partners with Lionsgate to develop AI video tools using studio's movie catalog
Generative AI Applications
Sep 18, 2024
Funding
QMill raises EUR 4 million in seed funding to provide quantum computing industrial applications
Quantum Computing
Sep 18, 2024
Product updates
QuiX Quantum launches 'Bia' quantum cloud computing service for quantum solutions
Quantum Computing
Sep 18, 2024
Partnerships
Oxford Ionics and Infineon Technologies partner to build portable quantum computer for Cyberagentur
Quantum Computing
Sep 18, 2024
Partnerships
Product updates
Tencent Ai Lab launches EzAudio AI for text-to-audio generation with Johns Hopkins University
Foundation Models
Sep 18, 2024
Funding
TON secures USD 30 million in investment from Bitget and Foresight Ventures
Web3 Ecosystem
Sep 18, 2024
Funding
Hemi Labs raises USD 15 million in funding to launch blockchain network
Web3 Ecosystem
Sep 18, 2024
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Machine Learning Infrastructure
Sep 18, 2024
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Data Infrastructure & Analytics
Sep 18, 2024
Precision Medicine

Precision Medicine

Aug 7, 2024

Seed Therapeutics partners with Eisai for molecular glue degraders development

Partnerships

  • Seed Therapeutics, a biotech firm specializing in molecular glue degraders, has partnered with Eisai, a pharmaceutical company, in a deal worth over USD 1.5 billion. The collaboration aims to discover, develop, and commercialize novel molecular glue degraders for undisclosed neurodegeneration and oncology targets. Seed Therapeutics will focus on preclinical discovery, while Eisai will contribute its neurodegeneration and cancer research expertise.

  • As part of the agreement, Eisai will have exclusive rights to develop and commercialize compounds from the collaboration. Seed Therapeutics will receive upfront and milestone payments of up to USD 1.5 billion, plus tiered royalties.

  • Concurrently, Seed Therapeutics has launched a Series A-3 financing round, led by Eisai and with a first close of USD 24 million, to accelerate its clinical development programs and expand its targeted protein degradation platform.

  • Seed Therapeutics is a biotechnology company specializing in developing novel therapeutics using proprietary molecular glue technology. The company primarily focuses on creating treatments for severe diseases, including cancer, neurodegeneration, and infectious diseases.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.